ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,311.60
0.77%
Brent Oil
83.25
0.15%
Bitcoin
64,149.74
0.24%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. vTv Therapeutics Inc (VTVT)

  7. vTv Therapeutics Inc (VTVT) News

vTv Therapeutics (VTVT)

vTv Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VTVT
DateTimeSourceHeadlineSymbolCompany
19/03/202412:30PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITNASDAQ:VTVTvTv Therapeutics Inc
13/03/202412:00GlobeNewswire Inc.vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
07/03/202421:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
07/03/202419:34Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VTVTvTv Therapeutics Inc
06/03/202400:52Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:VTVTvTv Therapeutics Inc
05/03/202413:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
04/03/202413:00GlobeNewswire Inc.vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesNASDAQ:VTVTvTv Therapeutics Inc
01/03/202413:00GlobeNewswire Inc.vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:VTVTvTv Therapeutics Inc
01/03/202400:34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
28/02/202414:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
28/02/202414:14Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VTVTvTv Therapeutics Inc
28/02/202413:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
28/02/202413:00GlobeNewswire Inc.vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundNASDAQ:VTVTvTv Therapeutics Inc
22/02/202421:00PR Newswire (US)CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCENASDAQ:VTVTvTv Therapeutics Inc
22/12/202321:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
19/12/202321:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
12/12/202321:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
20/11/202321:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
15/11/202313:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
15/11/202313:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
09/11/202321:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTVTvTv Therapeutics Inc
09/11/202321:30GlobeNewswire Inc.vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
09/11/202321:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
08/11/202313:00GlobeNewswire Inc.vTv Therapeutics to Participate at the Stifel 2023 Healthcare ConferenceNASDAQ:VTVTvTv Therapeutics Inc
02/11/202312:00GlobeNewswire Inc.vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical OfficerNASDAQ:VTVTvTv Therapeutics Inc
01/11/202312:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
01/11/202312:00GlobeNewswire Inc.vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 MillionNASDAQ:VTVTvTv Therapeutics Inc
27/09/202313:30PR Newswire (US)CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19NASDAQ:VTVTvTv Therapeutics Inc
26/09/202313:30PR Newswire (US)Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic CancerNASDAQ:VTVTvTv Therapeutics Inc
25/09/202321:20Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:VTVTvTv Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VTVT

Your Recent History

LSE
BIRD
Blackbird
LSE
FUM
Futura Medical
LSE
JSE
Jadestone Energy
LSE
AGL
Angle
LSE
APTA
Aptamer
LSE
INSG
Insig Ai
LSE
SCE
Surface Transforms
LSE
OXB
Oxford Biomedica
LSE
XTR
Xtract Resources
LSE
EMH
European Metals
LSE
MNL
Manchester & London Inve...
LSE
MIN
Minoan
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved